A novel immune-related gene-based prognostic signature to predict biochemical recurrence in patients with prostate cancer after radical prostatectomy.

Lv, Daojun; Wu, Xiangkun; Chen, Xi; Yang, Shuxin; Chen, Wenzhe; Wang, Ming; Liu, Yongda; Gu, Di; Zeng, Guohua

Lv, Daojun; Wu, Xiangkun; Chen, Xi; Yang, Shuxin; Chen, Wenzhe; Wang, Ming; Liu, Yongda; Gu, Di; Zeng, Guohua.

Afiliação

Lv D; Guangdong Key Laboratory of Urology, Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Wu X; Guangdong Key Laboratory of Urology, Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Chen X; Department of Urology, Guangzhou 12th People's Hospital, Guangzhou, Guangdong, China.
Yang S; Guangdong Key Laboratory of Urology, Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Chen W; Guangdong Key Laboratory of Urology, Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Wang M; Guangdong Key Laboratory of Urology, Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Liu Y; Guangdong Key Laboratory of Urology, Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. 13719007083@163.com.
Gu D; Guangdong Key Laboratory of Urology, Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. di.gu@doctors.org.uk.
Zeng G; Guangdong Key Laboratory of Urology, Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. gzgyzgh@vip.sina.com.

Cancer Immunol Immunother ; 70(12): 3587-3602, 2021 Dec.

Article em En | MEDLINE | ID: mdl-33934205

Assuntos

Recidiva Local de Neoplasia/genética; Recidiva Local de Neoplasia/patologia; Neoplasias da Próstata/genética; Neoplasias da Próstata/patologia; Linfócitos T CD4-Positivos/imunologia; Bases de Dados Genéticas; Humanos; Macrófagos/imunologia; Masculino; Mastócitos/imunologia; Gradação de Tumores/métodos; Recidiva Local de Neoplasia/imunologia; Recidiva Local de Neoplasia/cirurgia; Prognóstico; Prostatectomia/métodos; Neoplasias da Próstata/imunologia; Estudos Retrospectivos; Fatores de Risco; Linfócitos T Reguladores/imunologia; Microambiente Tumoral/imunologia

Palavras-chave

Biochemical recurrence; Immunotherapy; Prognosis; Prostate cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Recidiva Local de Neoplasia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google